ZLSCF (ZYUS Life Sciences) Policy Acquisition Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLSCF ZYUS Life Sciences Corp ZLSCF
21 GF Score
Price $0.23
GF Value $0.57
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.

ZLSCF
21GF Score
ZYUS Life Sciences Corp ZLSCF
Policy Acquisition Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ZYUS Life Sciences (ZLSCF) Overvalued in 2026?

Based on GuruFocus' analysis, ZYUS Life Sciences stock appears to be undervalued. The current stock price of $0.23 is trading 60.2% below its estimated GF Value™ of $0.57. GuruFocus considers ZYUS Life Sciences to be Possible Value Trap.

Key valuation signals for ZLSCF:

  • Policy Acquisition Expense:
  • GF Value™: $0.57 vs. price of $0.23 (60.2% below fair value)
  • GF Score™: 21/100 with 6 warning signs

No single metric tells the full story. See the ZLSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ZYUS Life Sciences Business Description

Other Exchanges ZYUS:Canada
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
21GF Score

Get the complete analysis for ZLSCF

Policy Acquisition Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.23
Price
$0.57
GF Value